ArticleBioinformatics (Oxford, England)2018
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning.
Article in Bioinformatics (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 298 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
298 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Pooled it
- A Machine Learning Approach for Predicting Synergism of Mixtures of Compounds in Treating Cancers.International journal of molecular sciences · 2026Article
- Article
- Targeting GLUTs in Cancer: Mechanisms, Combination Strategies, and Translational Challenges.Current medical science · 2026Review
- Artificial intelligence in oncology: linking biological discovery to clinical utility.Molecular cancer · 2026Review
- Machine learning and AI for cancer research and care: a review of applications, limitations, and future directions.Journal of the Egyptian National Cancer Institute · 2026Review
- Momentum contrast-enhanced multimodal representation learning for drug synergy prediction.Bioinformatics (Oxford, England) · 2026Article
- Closing the Translational Gap: Closed-Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics.Cancer medicine · 2026Review
- GATESynergy: Integrating Molecular Global-Local Aggregator and Hierarchical Gene-Gated Encoder for Drug Synergy Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- DeepSynBa: actionable drug combination prediction with complete dose-response profiles.Bioinformatics (Oxford, England) · 2026Article
- Unified heterogeneity-aware benchmark of drug synergy prediction: a cross-study analysis of traditional machine learning and graph deep learning models.Journal of cheminformatics · 2026Article
- A dual granular balanced deep forest model for effective drug combination prediction.iScience · 2026Article
- Innovative strategies to overcome cancer drug resistance: from nanodelivery systems to targeted therapeutics.Discover oncology · 2026Review
- Predicting gene essentiality and drug response from preclinical perturbation screens with layered ensemble of autoencoders and predictors.Scientific reports · 2026Article
- CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Interpretable graph deep learning framework for drug synergy prediction by integrating functional and clinical similarities.NPJ digital medicine · 2026Article
- Enhancing Drug Response Prediction in Epilepsy with Emerging Multimodal Models: Focus on Clinical, Pharmacologic, and Genomic Factors.CNS drugs · 2026Review
- Data-driven design and screening of novelRSC advances · 2026Article
- AI and network biology for rational polypharmacology in signaling drug design: a review.NPJ precision oncology · 2026Review
- A causal inference framework for identifying essential genes to enhance drug synergy prediction.Bioinformatics (Oxford, England) · 2026Article
238 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: While drug combination therapies are a well-established concept in cancer treatment, identifying novel synergistic combinations is challenging due to the size of combinatorial space. However, computational approaches have emerged as a time- and cost-efficient way to prioritize combinations to test, based on recently available large-scale combination screening data. Recently, Deep Learning has had an impact in many research areas by achieving new state-of-the-art model performance. However, Deep Learning has not yet been applied to drug synergy prediction, which is the approach we present here, termed DeepSynergy. DeepSynergy uses chemical and genomic information as input information, a normalization strategy to account for input data heterogeneity, and conical layers to model drug synergies. Results: DeepSynergy was compared to other machine learning methods such as Gradient Boosting Machines, Random Forests, Support Vector Machines and Elastic Nets on the largest publicly available synergy dataset with respect to mean squared error. DeepSynergy significantly outperformed the other methods with an improvement of 7.2% over the second best method at the prediction of novel drug combinations within the space of explored drugs and cell lines. At this task, the mean Pearson correlation coefficient between the measured and the predicted values of DeepSynergy was 0.73. Applying DeepSynergy for classification of these novel drug combinations resulted in a high predictive performance of an AUC of 0.90. Furthermore, we found that all compared methods exhibit low predictive performance when extrapolating to unexplored drugs or cell lines, which we suggest is due to limitations in the size and diversity of the dataset. We envision that DeepSynergy could be a valuable tool for selecting novel synergistic drug combinations. Availability and implementation: DeepSynergy is available via www.bioinf.jku.at/software/DeepSynergy. Contact: klambauer@bioinf.jku.at. Supplementary information: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.